Effects of VEGFA and ANGPT2 Antibodies on the Activation of Microglia in the Early Stages of Streptozotocin‐Induced Pathogenesis of Diabetic Retinopathy
Genes to Cells · 2025
DOI: 10.1111/gtc.70036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes to Cells, 2025. Verfasst von Toshiro Iwagawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Retinal Biology and Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Microglia, Angiopoietin-2, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical Co. Ltd.
Abstract (Originalsprache)
Diabetic retinopathy (DR) is known as a microvascular complication, in which various inflammatory symptoms, including activation of microglia, are observed. A model of hyperglycemia resembling type 1 diabetes mellitus (DM) induced in mice by intraperitoneal injection of streptozotocin (STZ) has been widely used. We examined the effects of anti‐ vascular endothelial growth factor A (VEGFA) and anti‐angiopoietin‐2 (ANGPT2) antibodies in addition to a bispecific antibody against VEGFA and ANGPT2 by intravitreously administrated to the eyes on early signs, especially the activation of microglia in STZ‐treated mice eyes. After 14 weeks of STZ administration, alterations in activity by ERG and CD31 staining patterns were not observed. Although a difference in the number of microglia in the retina between normal and STZ‐model retinas was not observed, the morphology of microglia had changed from ramified in control to amoeboid shape in STZ model at 4 days after the antibodies injection. Detailed morphological examination showed decreases in area, ramification index, and tree length in the STZ‐model retinas compared with normal retinas. Recovery from these decreases was demonstrated mainly by the administration of the bispecific antibody. These results suggest that anti‐VEGFA/ANGPT2 therapy may suppress the activation of microglia in the early stages of DR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Retinal Biology and Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Product Research Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
- Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan.
- Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Toshiro Iwagawa, Yuta Inokuchi, Sumiko Watanabe
Förderung
- Chugai Pharmaceutical Co. Ltd
Zitieren
APA
Iwagawa, T., Inokuchi, Y., Saita, K., Soeda, T., Usui-Ouchi, A., Aihara, M., & Watanabe, S. (2025). Effects of VEGFA and ANGPT2 Antibodies on the Activation of Microglia in the Early Stages of Streptozotocin‐Induced Pathogenesis of Diabetic Retinopathy. Genes to Cells. https://doi.org/10.1111/gtc.70036
Vancouver
Iwagawa T, Inokuchi Y, Saita K, Soeda T, Usui-Ouchi A, Aihara M, et al. Effects of VEGFA and ANGPT2 Antibodies on the Activation of Microglia in the Early Stages of Streptozotocin‐Induced Pathogenesis of Diabetic Retinopathy. Genes to Cells. 2025. doi:10.1111/gtc.70036
BibTeX
@article{Iwagawa2025,
author = {Iwagawa, Toshiro and Inokuchi, Yuta and Saita, Kosuke and Soeda, Tetsuhiro and Usui-Ouchi, Ayumi and Aihara, Makoto and Watanabe, Sumiko},
title = {Effects of VEGFA and ANGPT2 Antibodies on the Activation of Microglia in the Early Stages of Streptozotocin‐Induced Pathogenesis of Diabetic Retinopathy},
journal = {Genes to Cells},
year = {2025},
doi = {10.1111/gtc.70036}
}
EUVIMED